Camber Pharmaceuticals Inc

Camber Pharmaceuticals is excited to announce the addition of Dicyclomine Hydrochloride Capsules, USP. Dicyclomine Hydrochloride Capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome. Dicyclomine Hydrochloride Capsules, USP are available in 10 mg strength, packaged in 100 and 1000 count bottles. To find out more information on Dicyclomine Hydrochloride Capsules, USP please visit: https://lnkd.in/eQtcNziY

For over a decade, Camber's associates have proudly supported the Marine Toys for Tots Foundation, a heartfelt initiative led by the United States Marine Corps Reserve.  We are deeply grateful to the heroes of the United States Marine Corps Reserve for their unwavering dedication to brightening the holidays for so many children. Your efforts inspire us all to give back and make a difference.

As the holiday season approaches, we thank you for your support and partnership throughout the year. Our offices will be closed on Wednesday, December 25, and Wednesday, January 1. Wishing you and your loved one’s warmth, joy, and success this season!

Two years ago, Camber added Solifenacin to its portfolio as the generic version of Vesicare®. Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

In 2018, Camber added Ritonavir to its portfolio as a cost-effective generic alternative to Norvir®. Ritonavir tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This addition reflects Camber’s dedication to providing affordable, high-quality antiretroviral treatments.

In 2020, Camber introduced Mesalamine Suppositories, offering a high-quality generic alternative to Canasa®. Mesalamine Suppositories are an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. By 2024, Camber had reached an impressive milestone of 45 ANDA approvals, further expanding our portfolio to nearly 200 product families and 600 SKUs.

Camber Pharmaceuticals is excited to announce the addition of Erlotinib Tablets. Erlotinib Tablets are a kinase inhibitor indicated for:    • The treatment of patients with metastatic non-small cell lung cancer (NSCLC)    • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles. To find out more information on Erlotinib Tablets please visit: https://lnkd.in/eQk5rusA

The Camber team extends our warmest wishes to all our valued partners and friends for a joyful and healthy holiday season. Reflecting on this year, we are grateful for your continued support and partnership. We invite you to enjoy this heartfelt message from your partners at Camber.

Phenylketonuria (PKU) is a rare genetic disorder that, if untreated, can lead to intellectual disabilities, seizures, and learning difficulties. In 2023, Camber introduced Sapropterin Dihydrochloride Tablets and PFOS (generic for Kuvan®). Sapropterin Dihydrochloride tablets and PFOS are indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age or older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Together, we’re committed to improving access to vital treatments for rare conditions like PKU.

Join Camber Specialty at Booth 1235 during the ASHP Midyear Clinical Meeting & Exhibition, now until December 12th in New Orleans! Explore our latest specialty generic product launches and connect with Tom DeStefano, EVP, and Gary Doucette, Senior Director, to discover how Camber Specialty advances solutions to address critical healthcare needs. #ashp24